Family Care Hospitals Board to Approve FY26 Audited Results April 27

OTHER
Whalesbook Corporate News Logo
AuthorAarav Shah|Published at:
Family Care Hospitals Board to Approve FY26 Audited Results April 27
Overview

Family Care Hospitals Ltd has scheduled a board meeting for April 27, 2026, to approve its audited financial results for the fiscal year and quarter ending March 31, 2026. The company also closed its trading window from April 1, 2026, until 48 hours after results are announced, to prevent insider trading, as required by SEBI rules.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

Board Meeting Set for April 27 to Review FY26 Audited Results

Family Care Hospitals Ltd announced its Board of Directors will meet on April 27, 2026, to approve its audited standalone financial results for the fiscal year and quarter ended March 31, 2026. The company also implemented a trading window closure for designated employees and their relatives, effective April 1, 2026, until 48 hours after the results are released. This move aligns with SEBI's insider trading rules to prevent the misuse of sensitive information.

Why This Matters

Approving audited financial results is key for corporate governance. It gives stakeholders a clear picture of the company's financial health and performance for the fiscal year. For investors, these results will provide important insights into operational efficiency and profitability. The trading window closure also helps maintain market fairness by preventing unfair advantages from insider knowledge, promoting transparency.

Company Background

Family Care Hospitals has a notable corporate history, including several name changes, most recently becoming Family Care Hospitals Limited in June 2022. The company raised ₹4.67 crore through a preferential allotment of share warrants in Q3 FY26. Operations have shifted significantly; the company vacated its Mira Road hospital in October 2024 and is now focusing on diagnostic and pharmacy services via partnerships. Financial performance has been difficult, with Q3 FY26 revenue at ₹0.06 crore and a net loss of ₹0.96 crore. In FY25, shareholder funds dropped by 76.94%, alongside negative operating cash flow, indicating severe financial strain.

What Changes Now

  • Shareholders will gain access to the official audited FY26 financial performance.
  • The audited results could impact investor sentiment and stock valuation.
  • The trading window will reopen, allowing designated individuals to trade securities under insider trading rules.
  • The company may offer commentary on its strategy and outlook with the results.

Risks to Watch

The company has a history of regulatory issues. In June 2025, SEBI fined Family Care Hospitals ₹34 lakh for improper related-party transactions and failure to account for rent arrears. SEBI had previously fined the company ₹15 lakh in March 2024 for not disclosing debt and approving related-party transactions broadly. Concerns about financial viability remain high, driven by falling revenues, increasing losses, and shrinking shareholder funds. The closure of its Mira Road hospital operations highlights ongoing operational difficulties and its strategic shift.

Peer Comparison

Family Care Hospitals operates in India's healthcare sector against larger competitors. For FY25, Apollo Hospitals reported ₹21,794 crore, Max Healthcare ₹7,028 crore, and Fortis Healthcare ₹7,783 crore in revenue. Max Healthcare also leads in revenue per bed, suggesting greater operational efficiency among these major players.

Key Metrics

  • In Q3 FY26 (ended December 31, 2025), Family Care Hospitals reported ₹0.06 crore in total income and a net loss of ₹0.96 crore (Standalone).
  • Shareholder funds decreased by 76.94% over the past year, falling from ₹58.37 crore to ₹13.46 crore as of FY25 (Standalone).

What to Track Next

  • The full FY26 financial performance figures once announced.
  • Management's commentary on future strategies and challenges with the results.
  • Updates on the operational pivot to diagnostic and pharmacy services and its success.
  • The company's progress in managing financial pressures and governance issues.
  • Any further regulatory announcements or actions.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.